BioAgilytix to Purchase Australia-based 360biolabs®

BioAgilytix | August 17, 2021

BioAgilytix Labs,a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, announced today that it signed a definitive agreement to purchase 360biolabs®, the most comprehensive contract research organization in Australia. The transaction will expand BioAgilytix's global footprint into a jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials and adds further capacity by joining 360biolabs' internationally recognised Quality systems in Melbourne, Victoria with BioAgilytix's existing laboratories in Durham, North Carolina; Boston, Massachusetts; and Hamburg, Germany.

Located in Australia's biomedical and clinical research hub, 360biolabs offers world-class virology and immunology expertise, with BSL 2 and 3 laboratories, biomarker and immune monitoring capabilities with a state-of-the-art flow cytometry suite, molecular biology PCR suite and expansive bioanalytical LC-MS/MS small molecule capabilities.

"This planned acquisition is part of our strategic growth strategy to expand our capacity, expertise and agility to serve customers across all geographies, and we look forward to welcoming the 360biolabs team and integrating the business," said Jim Datin, President and CEO of BioAgilytix. "Joining forces makes sense for our two organizations, but most importantly for our combined clients and the patients they serve. BioAgilytix and 360biolabs are already culturally aligned in our focus on doing science right, on time, the first time. Together, we will not only create significant scientific synergies but also generate new innovations and help bring future life-changing therapeutics to patients more rapidly around the globe."  

"From the launch of 360biolabs in 2015, our strategic vision was to build a global speciality laboratory, providing support to enable future medicines for human health," said Angela Luttick, 360biolabs Cofounder and Executive Vice President, Business Development. Added 360biolabs Cofounder and CEO Alistair Draffan, "Finding a like-minded partner, driven by a team-focused culture of excellence with an international reputation, US and European presence, will drive our strategic expansion and support our clients' clinical development programs." Melinda Pryor, Cofounder and Executive Vice President, Clinical stated, "We're excited to join forces with the BioAgilytix team, a company that shares our strong scientific track record and commitment to quality and service. Together, we have the capabilities and capacity to meet all challenges, especially in this time of pandemic, and create enduring opportunities for a brighter future."

The Burnet Institute, a global medical research and public health organisation, is a Cofounder and majority shareholder of 360biolabs. Burnet Institute Director and CEO, Professor Brendan Crabb AC said, "Burnet Institute is proud of its involvement in the foundation of 360biolabs. It is the right time, with the growing need for high quality clinical trial support, for a company of the scale, capability, and reputation of 360biolabs to join with BioAgilytix and expand their capacity to service their customers and facilitate high quality translational medical research."

The acquisition is subject to Australian Foreign Investment Review Board ("FIRB") requirements and, subject to receipt of FIRB approval, is expected to close in the third quarter of 2021. BioAgilytix selected White & Case as legal counsel to oversee the closing of the acquisition, with Lazard Australia and Allens representing 360biolabs.

About BioAgilytix
BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina's Research Triangle Park, the Cambridge area of Massachusetts, and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product release testing, stability testing, etc.). BioAgilytix also offers diagnostic testing services at its CLIA-certified, CAP-accredited Boston laboratory.

About 360biolabs®
360biolabs® is the leading and most comprehensive specialty laboratory in the Australia & New Zealand region. Our expert pharmacokinetic (PK) and pharmacodynamic (PD) assay services support small molecule, biologic, vaccine and other innovative therapeutic solutions to human health. A world class and industry experienced technical team, known for their ability to successfully deliver technically challenging assays, 360biolabs® supports global Pharmaceutical and biotech companies in a diverse and growing range of therapeutics areas.


Experiome Biotech Pvt Ltd is your destination for project dissertations, trainings, workshops, internships, thesis writing, project writing and many more biotech research and training needs.


Experiome Biotech Pvt Ltd is your destination for project dissertations, trainings, workshops, internships, thesis writing, project writing and many more biotech research and training needs.

Related News


Kite and Arcellx Close Deal to Develop and Market Late-stage Clinical CART-ddBCMA

Kite Pharma and Arcellx | January 31, 2023

On January 30, 2023, Kite and Arcellx, Inc. informed that they have completed their previously-announced global strategic collaboration to co-develop and co-market CART-ddBCMA. CART-ddBCMA is Arcellx's lead late-stage candidate for treating patients with relapsed or refractory multiple myeloma. For the majority of patients, multiple myeloma is an incurable disease; hence, there is a continuing demand for treatments that are not only effective but also secure and easily available. Arcellx's T-cell treatment, CART-ddBCMA, uses the company's unique synthetic binder, the D-Domain, and is now being studied in Phase 2 pivotal trials. Kite and Arcellx will work together to develop and market the CART-ddBCMA asset in the United States, while Kite will handle sales and marketing for the product in all other regions. About Kite Pharma Kite, a Gilead company, is a global biopharmaceutical company with its headquarters in Santa Monica (California). Cell therapy, which aims to treat and maybe even cure cancer, is the company's main area of research and development. Kite, the industry leader in cell therapy, has successfully administered CAR T-cell treatment to more patients than any other company. Process development, vector production, clinical trial supply, and commercial product manufacturing are all part of Kite's expansive in-house cell therapy manufacturing network, the most extensive in the world. About Arcellx Clinical biotechnology firm Arcellx, Inc. is rethinking cell treatment by developing novel immunotherapies for patients with cancer and other fatal diseases. The company considers cell therapies one of the most promising areas of modern medicine. Its goal is to improve the quality of life for people everywhere by creating safer, more effective, and widely available cell therapies. CART-ddBCMA is the principal product candidate being developed by Arcellx and is now in Phase 2 pivotal trials for treating relapsed or refractory multiple myeloma (r/r MM). The FDA has recognized CART-potential ddBCMAs by designating them as a regenerative medicine advanced therapy, an orphan drug, and a fast-track product.

Read More


GenScript Announces Expansion of Singapore Facility

GenScript | March 03, 2023

GenScript Biotech Corporation, a leading tools and services provider for life-science research, recently announced the expansion of its Singapore facility to provide a high-quality gene synthesis service. This expansion has added 976 square meters to the facility, bringing its total size to 3,500 square meters, making it the third-largest facility for GenScript globally. This development will also increase the staff at the Singapore facility to 150. In February 2022, GenScript Asia-Pacific opened a recombinant protein production facility, which will now offer an advanced gene synthesis service. This expansion is a significant step towards GenScript's aim to provide top-notch services required for novel vaccine and therapeutic development in the life-sciences field. The Singapore facility uses modernized, automated workstations that can synthesize more than 400 genes daily, ensuring precise measurement, eliminating human error, and providing a consistently high-quality product. The new facility's goal is to decrease project turnaround time for a more global mix of clients while maintaining customer data security. The new facility's capacity is dedicated to gene and cell therapy research and vaccine development programs. GenScript's Life Science Group President, Dr. Ray Chen, commented, "We understand that global supply is a huge challenge, and we remain committed to expanding our reach to meet the increasing demand for our customers worldwide. At GenScript, we take great pride in our ability to provide reliable and efficient solutions to our customers, and we are fully committed to delivering on this promise. As we continue to expand our global footprint, we remain dedicated to providing the highest-quality products and services to our customers, wherever they may be located." (Source – PR Newswire) About GenScript Founded in 2002, GenScript is a leading biotech firm. It has a global presence across the EU, North America, Greater China and Asia Pacific and has served more than 300,000 customers from over 160 countries and regions around the world. With more than 5,000 employees, it is dedicated to providing premier, convenient, and reliable products and services. The company strongly focuses on technology development, with over 100 patents and 270 patent applications in fields such as immunotherapy, synthetic biology, chemical synthesis, antibody design and bioinformatics. GenScript's products and services have been cited in 74,700 scientific papers worldwide as of June 2022. The company's vision is to become the most reliable biotech company in the world, working towards the betterment of human and environmental health through biotechnology.

Read More


Premier Research and InSilicoTrials Partner for Rare Disease Therapy Development

Premier Research | March 14, 2023

Premier Research has partnered with InSilicoTrials, a leader in using artificial intelligence (AI) and computational modeling and simulation (CM&S) to speed up the development of new therapies and medical devices. Premier Research helps biotech and device companies take their ideas from the idea stage to the commercialization stage. The aim of the partnership is to make it easier, faster, and safer for treatments for rare diseases to get approval from the government. CM&S and AI have made it possible to use virtual patients in clinical trials in whole or in part, which the FDA approves of in some cases. In silico trials make it possible to create fake control or treatment arms, help figure out how to sign up patients, and predict the safety and effectiveness of new drugs and medical devices more accurately. The use of synthetic control arms generated using in silico CM&S techniques represents a powerful tool for enabling non-feasible rare disease research, both preclinical and clinical research. In the last five years, Premier Research has been in charge of more than 240 rare disease studies for a wide range of indications. This shows that the company is committed to orphan drug development for a long time. Premier Research is continuing to put money into trials for rare diseases by partnering with InSilicoTrials. One major advantage of in silico simulation is the ability to investigate 'what if' scenarios, particularly in rare diseases where a larger patient population does not exist. By using biological, molecular, or genetic data to describe rare diseases, in silico models can make synthetic control arms. This, along with Premier Research's expertise in clinical and preclinical development, execution, and regulatory aspects of small population trials, can shorten the time it takes to make effective treatments for rare diseases. The partnership between Premier Research and InSilicoTrials will focus on smarter in silico study design, leading to a more effective pre-clinical review of trial design parameters and faster submission-ready studies. CEO of InSilicoTrials Luca Emili says that combining modeling and simulation with AI is the best way to improve the R&D process in drug development. This is because it allows sponsors to speed up the development of new treatments, make medical products safer, and lower R&D costs. About Premier Research Premier Research is a global company that does clinical research, product development, and consulting. It focuses on using new technologies to design and run smart studies and trials. With more than 2,500 employees in 75 countries, it has a lot of experience in certain therapeutic areas and uses. The company is committed to empowering its customers to meet the unmet needs of patients and offers great benefits and flexible working conditions.

Read More